Actively Recruiting
Comparing One Versus Three Sessions of Heated Chemotherapy After Surgery for Pseudomyxoma Peritonei
Led by Beijing Tsinghua Chang Gung Hospital · Updated on 2026-01-09
132
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of one versus three sessions of hyperthermic intraperitoneal chemotherapy HIPEC following cytoreductive surgery CRS in patients with pseudomyxoma peritonei PMP. The study aims to determine if three HIPEC sessions improve progression-free survival PFS and overall survival OS compared to one session, and to assess differences in complications, organ toxicity, and quality of life between the two treatment schedules. Participants will be randomly assigned to two groups the control group will receive a single intraoperative HIPEC session after CRS, while the experimental group will receive two additional HIPEC sessions on postoperative days 2 and 4 at reduced drug doses. Safety checks for side effects are scheduled on days 1, 3, 5, 7, and 10 after HIPEC. After one month, eligible participants may receive six cycles of standard postoperative chemotherapy. During the study, participants will attend follow-up visits including physical exams, blood tests for tumor markers, CT scans, and quality-of-life questionnaires. The primary outcomes measured are the one-year progression-free survival rate and serious adverse events within one month after surgery. Secondary outcomes include progression-free survival and overall survival up to three years postoperatively. Long-term monitoring will continue for several years to assess ongoing health and quality of life.
CONDITIONS
Brief Title
One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei
Research Team
R
Rui Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here